GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports that on 2 April 2026 it repurchased 335,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,093.00p to 2,161.00p per share, with a volume‑weighted average price of 2,121.37p.
The acquired shares will be held as Treasury shares. Since 17 February 2026, GSK has bought back 16,901,521 ordinary shares. After this transaction, it holds 256,792,615 shares in treasury and has 4,059,387,166 ordinary shares in issue excluding treasury, which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is confirmed at 6.33%.
GSK plc reports that it bought back 345,000 ordinary shares of 31¼ pence each on 01 April 2026 through BNP Paribas under its existing share buyback programme. The volume-weighted average price paid was 2,106.14p per share, within a range of 2,086.00p to 2,122.00p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 16,566,521 ordinary shares under this programme. After this transaction, GSK holds 256,457,615 ordinary shares in treasury and has 4,059,722,166 ordinary shares in issue, which equals the total number of voting rights.
GSK states that, in line with DTR 5.5.1R, the voting rights attributable to ordinary shares held in treasury represent 6.32 per cent. Shareholders can use the 4,059,722,166 voting rights figure as the denominator when assessing disclosure thresholds under the UK Financial Conduct Authority’s rules.
GSK plc reported that its Chief People Officer, Diana Conrad, acquired American Depositary Shares (ADS) under a GSK pension plan. She acquired 428.137 ADS at $52.0278 per ADS on 2026-03-24 and 12.186 ADS at $54.4682 per ADS on 2026-03-30 on the New York Stock Exchange.
GSK plc reported its total voting rights as of 31 March 2026. The company had 4,316,179,781 issued ordinary shares of 31 ¼ pence each, with 256,112,615 shares held in treasury. This leaves 4,060,067,166 voting rights, which shareholders can use as the denominator for disclosure threshold calculations under UK transparency rules.
GSK plc reports that, acting through BNP Paribas, it repurchased 340,000 ordinary shares of 31¼ pence each on 31 March 2026 as part of its existing share buyback programme. Prices ranged from 2,064.00p to 2,086.00p per share, with a volume-weighted average price of 2,075.26p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 16,221,521 ordinary shares. After this transaction, GSK holds 256,112,615 shares in treasury and has 4,060,067,166 ordinary shares in issue, giving a total of 4,060,067,166 voting rights. Treasury shares represent 6.31% of the company’s voting rights under DTR 5.5.1R.
GSK plc has completed a reshaping of ownership in HIV specialist ViiV Healthcare as Pfizer exits its investment and Shionogi increases its stake. Shionogi’s economic interest in ViiV Healthcare rises to 21.7%, while GSK maintains a 78.3% majority interest.
ViiV Healthcare issued new shares to Shionogi for $2.125 billion, cancelled Pfizer’s holding, and paid $1.875 billion to Pfizer and a $0.250 billion special dividend to GSK. GSK’s previously recorded Pfizer put option liability was extinguished through retained earnings at completion, with the final fair value remeasurement recognised as an adjusting item in other operating income.
GSK plc repurchased 340,000 ordinary shares on 30 March 2026 through BNP Paribas under its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 2,045.00p and 2,070.00p, with a volume-weighted average price of 2,060.19p.
The purchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 15,881,521 ordinary shares. After this transaction, it holds 255,772,615 shares in treasury and has 4,060,407,166 ordinary shares in issue, which is also the total number of voting rights.
GSK confirms that, under DTR 5.5.1R, 6.30 per cent of its voting rights are attributable to ordinary shares held in treasury. The filing also provides a detailed schedule of buyback trades across the London Stock Exchange and CBOE Europe venues.
GSK plc reports that China’s National Medical Products Administration has accepted for review a new drug application for bepirovirsen to treat adults with chronic hepatitis B. The investigational antisense oligonucleotide showed statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well 1 and B-Well 2 trials.
Functional cure means hepatitis B virus DNA and hepatitis B surface antigen are undetectable in blood for at least 24 weeks after stopping all treatment, indicating immune control without medication. Current standard nucleos(t)ide analogue therapies typically achieve functional cure in only about 1% of patients.
Bepirovirsen, licensed from Ionis Pharmaceuticals, has Breakthrough Therapy designation in China, Fast Track designation in the US and SENKU designation in Japan, but is not yet approved anywhere. Chronic hepatitis B affects more than 250 million people worldwide and an estimated 75 million people in China, causing around 450,000 deaths a year in China.
GSK plc reports that China’s National Medical Products Administration has approved Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and older. Exdensur is described as the first and only ultra-long-acting biologic in China for this condition and is dosed twice yearly.
The approval is based on the phase III SWIFT-1 and SWIFT-2 trials, where depemokimab plus standard of care significantly reduced annualised asthma exacerbations compared with placebo plus standard of care. In SWIFT-1 and SWIFT-2, exacerbation rates fell by 58% and 48% over 52 weeks, and pooled data showed a 72% reduction in clinically significant exacerbations requiring hospital or emergency visits.
Across the SWIFT trials, depemokimab showed a safety and tolerability profile similar to placebo. GSK notes that more than 2 million people in China are affected by severe asthma and highlights that Exdensur is already approved for severe asthma, and in some regions for chronic rhinosinusitis with nasal polyps, in the US, Japan, the EU and the UK.
GSK plc reports that, through BNP Paribas, it repurchased 340,000 ordinary shares on 27 March 2026 under its existing share buyback programme at a volume‑weighted average price of 2,043.51p, within a 2,024.00p–2,060.00p range.
The shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 15,541,521 shares. After this transaction, GSK holds 255,432,615 shares in treasury and has 4,060,747,166 shares in issue, giving total voting rights of 4,060,747,166 and a 6.29% treasury holding.